GlassScriptPhysician profile
Peach Supupramai
NPI 1235766296
$1,800.05
in general payments reported to CMS, 2019-2025
10 companies · $542 in 2025
The $542 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.36 · 2023: $26.75 · 2024: $1,217 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $777.43 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $465.36 | 2024-2025 | Evenity, Repatha, Repatha |
| Lilly USA, LLC | $181.46 | 2024 | Mounjaro, Zepbound |
| Davol INC. | $161.85 | 2024 | Phasix Mesh |
| Phathom Pharmaceuticals, INC. | $108.28 | 2024 | Voquezna |
| Abbott Laboratories | $38.14 | 2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $18.93 | 2024 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $17.94 | 2025 | |
| Esperion Therapeutics, INC. | $16.30 | 2024 | Nexletol |
| Sebela Pharmaceuticals INC. | $14.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peach Supupramai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.